Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
European Society of Cardiology
Pharma
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
At the ESC conference, Alnylam presented data from a key trial which assessed Amvuttra as a treatment for transthyretin amyloid cardiomyopathy.
Kevin Dunleavy
Aug 30, 2024 10:06am
At ESC, AstraZeneca shows Farxiga's benefits across indications
Aug 28, 2023 10:10am
AZ's Farxiga looks set to gain a key 2nd nod in heart failure
Aug 29, 2022 8:08am
Lexicon aims to make its heart failure case with sotagliflozin
Aug 23, 2021 4:00am
AZ's Farxiga flips script on competitors with 26% CV risk cut
Sep 3, 2019 9:27am
Novartis looks for the bright side in failed Entresto study
Sep 1, 2019 8:30am
